裂谷热病毒（Rift Valley fever virus, ...

Currently There Are More Than 50 PROTAC Drugs In Clinical Trials And Majority Are For Cancer As Per Recent Study By Kuick ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...

Work at Dark Blue Therapeutics Ltd. has led to the identification of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a MLLT1 ...

Kymera Therapeutics is a biotech company with innovative technology targeting disease-causing proteins, offering promising ...

彭珂课题组聚焦高致病、高传播性病毒开展研究，在病毒感染引发宿主免疫系统紊乱、触发炎症因子风暴的致病机理中取得了一系列原创性研究成果，近年来以通讯作者（含共同）在 Cell ， Cell Research (2) ， Science Advances ， Cell Reports ， Cell Discovery (2) ， eLife (2) ， Plos Pathogens ， mBio ， ...

Astrazeneca AB has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon unit coupled to an androgen receptor (AR) targeting moiety via a linker acting as AR ...

An international research team led by Prof. Dr. Janosch Hennig from the University of Bayreuth has discovered how the TRIM25 ...

Human proteins undergo a variety of chemical modifications following their synthesis. These modifications regulate their structure, function, and stability. Researchers from the Bhogaraju Group at ...

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast CancerCasitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...

Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of the activation of T and natural killer (NK) cells in ...